United States

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

29 Sep 2016
Change (% chg)

$-1.10 (-3.97%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Akorn Inc files new drug application with FDA
Thursday, 15 Jan 2015 05:30pm EST 

Akorn Inc:Confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market difluprednate ophthalmic emulsion 0.05 pct.If approved, Akorn's ANDA product would be a generic version of Alcon's Durezol, which is a topical corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery as well as the treatment of endogenous anterior uveitis.  Full Article

Akorn Inc raises FY 2014 guidance
Thursday, 6 Nov 2014 07:32am EST 

Akorn Inc:Expects FY 2014 outlook to revenue range of $630 - $640 mln (prior range of $580 to $600 mln).Expects FY 2014 adjusted net income per diluted share (EPS) range of $1.13 - $1.15 (prior range of $1.00 to $1.05).Expects FY 2014 adjusted net income in the range of $136 - $138 mln (prior range of $118-$125 mln).Expects FY 2014 Adjusted EBITDA (Non-GAAP) in the range of $265 - $270mln (prior range of $230 - $240).FY 2014 revenue of $597 mln, net income of $122 mln, EBITDA of $230 mln and EPS of $1.03 - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Akorn relaunches Ofloxacin Otic solution

* Akorn relaunches Ofloxacin Otic solution Source text for Eikon: Further company coverage: